#### **Supplemental Information for:**

#### Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells

Xinxin Yuan<sup>1, 2 #</sup>, Niansong Qian<sup>3, #</sup>, Shukuan Ling<sup>2</sup>, Yuheng Li<sup>2</sup>, Weijia Sun<sup>2</sup>, Jianwei Li<sup>2</sup>, Ruikai Du<sup>2</sup>, Guohui Zhong<sup>2</sup>, Caizhi Liu<sup>2</sup>, Guotao Yu<sup>1</sup>, Dengchao Cao<sup>1, 2</sup>, Zizhong Liu<sup>2</sup>, Yinbo Wang<sup>2</sup>, Zhihong Qi<sup>1</sup>, Yingpeng Yao<sup>1</sup>, Fang Wang<sup>1</sup>, Jingjing Liu<sup>1</sup>, Shanshan Hao<sup>1</sup>, Xiaoyan Jin<sup>2</sup>, Yinlong Zhao<sup>2</sup>, Jianqi Xue<sup>2</sup>, Dingsheng Zhao<sup>2</sup>, Xingcheng Gao<sup>2</sup>, Shuai Liang<sup>2</sup>, Youyou Li<sup>2</sup>, Jinping Song<sup>2</sup>, Shuyang Yu<sup>1, \*</sup>, and Yingxian Li<sup>2, \*</sup>

1 State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agricultural University, Beijing 100193, China

2 State Key Lab of Space Medicine Fundamentals and Application, China Astronaut Research and Training Center, Beijing 100094, China

3 Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China

- # Equal contributions to this work
- \* Corresponding authors:
- Prof. Yingxian Li, Email: yingxianli@aliyun.com
- Prof. Shuyang Yu, Email: ysy@cau.edu.cn

## Supplementary Figure 1. The influence of primary tumor on osteoblasts before the occurrence of bone metastasis

**A.** Quantitative micro-CT analysis of BMD of recipient mice at different checkpoint from the indicated groups (n = 6 mice per group).

**B.** The values of micro-CT parameters (Tb.N, Tb.Sp) at the distal femur metaphysis from tumor-free and tumor-bearing mice. (n = 8 mice per group). Tb. N, trabecular number, Tb.Sp, trabecular separation.

**C.** Osteoblast surface/bone surface (Ob.S/BS) and osteoblast number/bone perimeter (N.Ob/B.Pm) of the proximal tibia of recipient mice from the indicated groups (n = 3 in each group).

**D.** Representative images of the osteocalcin (OCN) staining in tibia sections from tumor-free and tumor-bearing mice. Scale bar, 25 μm.

**E.** ELISA analysis of the bone formation marker PINP levels in serum of tumor-free (n = 6) and tumor-bearing mice (n = 5).

**F.** Representative images of anti-GFP staining of tibia section from tumor-free, tumor-bearing mice and mice with bone metastasis of SCP28 cells as a positive control at checkpoint of 5 weeks post implantation. The brown areas represent tumor. Scale bar, 50 μm.

**G.** The changes of body weight in recipient mice at different checkpoint from tumor-free (n = 8) and tumor-bearing mice (n = 7).

Cumulative data are means  $\pm$  SEM. \* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001 (unpaired Student's *t* test). All data are from at least three independent experiments.

# Supplementary Figure 2. The effect of SCP28 cell-secreted exosomes on osteoclasts and osteoblasts *in vivo*

**A.** Body weight of recipient mice treated with SCP28 exosomes or PBS (n = 6 in each group).

**B.** Analysis of the expression of osteoclast marker genes including *Acp5*, *Ctsk*, *Mmp9*, and *Nfatc1* in tibias and femurs from mice treated with exosomes (n = 5) or PBS as controls (n = 6), respectively. The relative expression of each target transcript (after normalization to the housekeeping *Gapdh* gene) in control mice was set as 1, and that in exosome-treated mice was normalized, accordingly.

**C.** Ob.S/BS and N.Ob/B.Pm of the proximal tibia from the indicated groups (n = 3 in each group).

**D.** Representative images of the OCN staining in tibia sections from recipient mice treated with SCP28 exosomes or PBS. Scale bar, 25 μm.

**E.** ELISA analysis of the level of PINP in serum of recipient mice treated with SCP28 exosomes (n = 5) or PBS (n = 6).

Cumulative data are means  $\pm$  SEM. \* P < 0.05 (unpaired Student's *t* test). All data are from at least three independent experiments.

## Supplementary Figure 3. The effect of SCP28 cell-secreted exosomes on osteoclasts and osteoblasts *in vitro*

**A.** Western blot analysis of expression of NFATc1 in BMM cell induced osteoclasts treated with or without SCP28 cell-secreted exosomes.

**B.** *Rab27a* mRNA level was analyzed in SCP28 cells treated with Rab27a siRNA or NC. The relative expression of *Rab27a* (after normalization to the housekeeping *Gapdh* gene) in NC samples was set as 1, and that in *siRab27a* samples was normalized, accordingly. \*\*\* P < 0.001 by Student's *t* test.

C. Western blot analysis of expression of NFATc1 in SCP28 cells treated with Rab27a siRNA or NC.

**D.** The amounts of exosomes secreted by SCP28 cells treated with *Rab27a* siRNA or GW4869 was analyzed by NanoSight.

**E.** Western blot analysis of expression of RUNX2 in osteoblasts treated with or without SCP28 cell-secreted exosomes.

**F.** Representative images of ALP staining in osteoblasts treat with SCP28 exosomes or not. Scale bar, 3 mm.

**G.** qRT-PCR analysis of *Alp*, *Col1a1*, and *Ocn* mRNA in osteoblasts treated with or without SCP28 cell-secreted exosomes. The relative expression was normalized to *Gapdh* gene which is set as 1. Cumulative data are means  $\pm$  SEM. \*\*\* *P* < 0.001 (unpaired Student's *t* test). All data are from at least three independent experiments.

## Supplementary Figure 4. SCP28 cells-secreted exosomes enhance bone metastasis of MDA-MB-231 tumor cells

A. Flowchart of the experimental processes and scheme of SCP28 cell-secreted exosome education and metastasis

**B.** BLI quantitation of dynamic bone metastasis of breast cancer MDA-MB-231 cells in recipient mice educated by SCP28 cell-secreted exosomes (n = 6) or controls (n = 7); \*\* P < 0.01 by two-way ANOVA.

C. Kaplan-Meier curve showing bone metastasis of MDA-MB-231 cells in recipient mice educated by SCP28 cell-secreted exosomes (n = 6) or controls (n = 7); \* P < 0.05 (log-rank test).

**D.** Representative BLI imaging showing the MDA-MB-231 cells localization on day 42 in recipient mice educated by SCP28 cell-secreted exosomes or controls.

**E.** Representative images showing three-dimensional architecture after micro-CT reconstruction of the distal femurs from recipient mice. Scale bars, up 1 mm; bottom 300 μm.

F. Quantitative micro-CT analysis of distal femurs from recipient mice educated by SCP28 cell-secreted exosomes (n = 5) or controls (n = 7), including BMD, SMI, Tb.N, Tb.Th, Tb.Sp and C.Th. \*P < 0.05; \*\*P < 0.01 by Student's *t* test.

**G.** Representative X-ray images (up) and quantification of osteolytic lesions (bottom) in MDA-MB-231 cell-implanted mice educated by SCP28 cell-secreted exosomes or controls (n = 7 per group). Arrows indicate osteolytic bone areas. \*\* P < 0.01 by Student's *t* test.

**H.** Representative images of H&E, TRAP, and OCN staining from MDA-MB-231 cell-implanted mice educated by SCP28 cell-secreted exosomes or controls. T, tumor; M, bone marrow. Scale bar, 25  $\mu$ m. Cumulative data are means  $\pm$  SEM. The statistical method indicated relatively. All data are from at least three independent experiments.

# Supplementary Figure 5. Bisphosphonate treatment attenuates pro-metastatic effect of breast cancer cell-derived exosomes in the bone

**A.** Representative images showing three-dimensional architecture after micro-CT reconstruction of the distal femurs from recipient mice. Scale bars, up 1 mm; bottom 300 μm.

**B**. Quantitative micro-CT analysis of distal femurs from control recipient mice with different treatment: Control, n = 5; BP, n = 4; exosomes, n = 5; exosomes + BP, n = 5, including BMD, SMI, Tb.N, Tb.Th, Tb.Sp and C.Th. \* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001 by one-way ANOVA.

Cumulative data are means  $\pm$  SEM. All data are from at least three independent experiments.

#### Supplementary Figure 6. SCP28 cell-derived exosomal miR-21 promotes osteoclastogenesis

**A.** Heatmap globally showing enriched miRNAs in SCP28 cell-secreted exosomes. Normalized expression level of miRNAs which are higher in the top 200 miRNAs was labeled on the top and the scale bar on the right.

**B.** Normalized miRNA expression levels for the top 17 miRNAs except *miR-21-5p* in SCP28 cell-secreted exosomes. The relative expression was normalized to *U6* gene which is set as 1. \* P < 0.05; \*\* P < 0.01; \*\*\*, P < 0.001 by Student's *t* test.

C. qRT-PCR analysis of *miR-21* level in exosomes secreted by MCF10A, MDA-MB-231, SCP28 and parental MDA-MB-231-LM2 cells. The relative expression was normalized to *miR-16* gene which are set as 1, respectively. \* P < 0.05; \*\* P < 0.01 by one-way ANOVA.

**D.** The expression of *miR-21* in SCP28 cells and exosomes was measured by qRT-PCR. The relative expression of *miR-21* in cell or exosomes was normalized to *U6* or *miR-16* gene which are set as 1, respectively. \* P < 0.05; \*\* P < 0.01 by one-way ANOVA

E. qRT-PCR analysis of *miR-21* level in SCP28 cells treated with miR-21 ShRNA or NC. The relative expression of *miR-21* was normalized to *U6* gene which is set as 1. \*\* P < 0.01 by Student's *t* test.

**F.** Representative images showing three-dimensional trabecular architecture after micro-CT reconstruction of the distal femoral metaphysis of mice. Scale bar, 300 μm.

G. Quantitative micro-CT analysis of distal femurs from mice in each experimental group, including BMD, SMI, Tb.Th, Tb.Sp and BV/TV. Control, n = 7; SCP28/NC, n = 6; SCP28/Sh-miR-21, n = 6. \* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001 by one-way ANOVA.

**H.** ELISA analysis of serum CTX-1 (ng/mL) in control (n = 7), SCP28/NC (n = 6) and SCP28/Sh-miR-21 (n = 7) mice. \*\* P < 0.01 by one-way ANOVA.

**I.** qRT-PCR analysis of the expression of osteoclast marker genes including *Acp5*, *Ctsk*, *Mmp9*, and *Nfatc1* in tibias and femurs from control (n = 6), SCP28/NC (n = 5) and SCP28/Sh-miR-21 (n = 5) mice. The relative expression of each target transcript (after normalization to the housekeeping *Gapdh* gene) in tumor-free mice was set as 1, and that in tumor-bearing mice was normalized, accordingly. \*

P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001 by one-way ANOVA.

Cumulative data are means  $\pm$  SEM. All data are from at least three independent experiments.



1 2 3 4 5 6 Weeks after tumor inoculation





Аср5

\*

Mmp9

O

00

0

0

□ Ctrl■ Exosomes

Ctsk

\*

0

20

15



0.0

0.0



0.0

0.1

0.0

00





В











#### Table S1. The primer list for qRT-PCR

Name	sense primer (5'-3')	anti-sense primer (5'-3')
mmu-Gapdh	ATGGTGAAGGTCGGTGTGAA	GTCGTTGATGGCAACAATCTCC
mmu-Nfatc1	ACGCTACAGCTGTTCATTGG	CTTTGGTGTTGGACAGGATG
mmu-Acp5	GCGACCATTGTTAGCCACATACG	CGTTGATGTCGCACAGAGGGAT
mmu-Mmp9	GCGGCCCTCAAAGATGAACGG	GCTGACTACGATAAGGACGGCA
mmu-Ctsk	GCGTTGTTCTTATTCCGAGC	CAGCAGAGGTGTGTACTATG
mmu-Alp	ATCTTTGGTCTGGCTCCCATG	TTTCCCGTTCACCGTCCAC
mmu-Ocn	CCAAGCAGGAGGGCAATA	TCGTCACAAGCAGGGTCA
mmu-Collal	GGGACCAGGAGGACCAGGAAGT	GGAGGGCGAGTGCTGTGCTTT
mmu-Pdcd4	AGCGGTTAGAAGTGGAGTTGCTGT	ACAAGGTGATTGACAGGCTGTTGC
hsa-Gapdh	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCATACTTCTCATGG
hsa-Rab27a	ACAACAGTGGGCATTGATTTCA	AAGCTACGAAACCTCTCCTGC
hsa-Pre-miR-21	CTTTAGGAGCATTATGAGC	ACTATCCCCATTTCTCCA
hsa- <i>miR-21-5p</i>	TAGCTTATCAGACTGATGTTGA	GAATCGAGCACCAGTTACGC
hsa- <i>miR-22-3p</i>	AAGCTGCCAGTTGAAGAACTGT	GAATCGAGCACCAGTTACGC
hsa- <i>miR-24-3p</i>	TGGCTCAGTTCAGCAGGAACAG	GAATCGAGCACCAGTTACGC
hsa-miR-27a-3p	TTCACAGTGGCTAAGTTCCGC	GAATCGAGCACCAGTTACGC
hsa-miR-27b-3p	TTCACAGTGGCTAAGTTCTGC	GAATCGAGCACCAGTTACGC
hsa-miR-100-5p	AACCCGTAGATCCGAACTTGTG	GAATCGAGCACCAGTTACGC
hsa-miR-148a-3p	TCAGTGCACTACAGAACTTTGT	GAATCGAGCACCAGTTACGC
hsa-miR-29a-3p	TAGCACCATCTGAAATCGGTTA	GAATCGAGCACCAGTTACGC
hsa-miR-320a	AAAAGCTGGGTTGAGAGGGCGA	GAATCGAGCACCAGTTACGC
hsa- <i>let-7i-5p</i>	TGAGGTAGTAGTTTGTGCTGTT	GAATCGAGCACCAGTTACGC
hsa-miR-3074-5p	GTTCCTGCTGAACTGAGCCAG	GAATCGAGCACCAGTTACGC
hsa- <i>miR-181a-5p</i>	AACATTCAACGCTGTCGGTGAGT	GAATCGAGCACCAGTTACGC
hsa-miR-26a-5p	TCAAGTAATCCAGGATAGGCT	GAATCGAGCACCAGTTACGC
hsa-miR-30d-5p	TGTAAACATCCCCGACTGGAAG	GAATCGAGCACCAGTTACGC
hsa- <i>miR-221-3p</i>	AGCTACATTGTCTGCTGGGTTTC	GAATCGAGCACCAGTTACGC
hsa- <i>miR-423-5p</i>	TGAGGGGCAGAGAGCGAGACTTT	GAATCGAGCACCAGTTACGC
hsa-miR-30a-5p	TGTAAACATCCTCGACTGGAAG	GAATCGAGCACCAGTTACGC
hsa- <i>miR-92a-3p</i>	TATTGCACTTGTCCCGGCCTGT	GAATCGAGCACCAGTTACGC
hsa- <i>miR-16</i>	TAGCAGCACGTAAATATTGGCG	GAATCGAGCACCAGTTACGC
cel-miR-39	GGCGCTACCTGTATCAATGG	GTGGTCAGCCAACTCGTCA
U6	CGCTTCGGCAGCACATATA	TTCACGAATTTGCGTGTCAT